SLC5A2 and hydrops fetalis: Thiazolidinediones and, possibly, certain dipeptidyl peptidase‐4 inhibitors increase the risk of HF hospitalization,5, 6 glucagon‐like peptide‐1 receptor agonists have shown a neutral effect,7, 8, 9, 10 and more recently, three sodium–glucose co‐transporter 2 (SGLT2) inhibitors, empagliflozin, canagliflozin and dapagliflozin, have shown a significant reduction in HF hospitalization.7, 8, 9, 10